Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 66(4): 2506-2523, 2023 02 23.
Article in English | MEDLINE | ID: mdl-36757090

ABSTRACT

Conjugation of synthetic triantennary N-acetyl-d-galactosamine (GalNAc) to small interfering RNA (siRNA) mediates binding to the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes, facilitating liver-specific uptake and siRNA-mediated gene silencing. The natural ß-glycosidic bond of the GalNAc ligand is rapidly cleaved by glycosidases in vivo. Novel GalNAc ligands with S-, and C-glycosides with both α- and ß-anomeric linkages, N-glycosides with ß-anomeric linkage, and the O-glycoside with α-anomeric linkage were synthesized and conjugated to siRNA either on-column during siRNA synthesis or through a high-throughput, post-synthetic method. Unlike natural GalNAc, modified ligands were resistant to glycosidase activity. The siRNAs conjugated to newly designed ligands had similar affinities for ASGPR and similar silencing activity in mice as the parent GalNAc-siRNA conjugate. These data suggest that other factors, such as protein-nucleic acid interactions and loading of the antisense strand into the RNA-induced silencing complex (RISC), are more critical to the duration of action than the stereochemistry and stability of the anomeric linkage between the GalNAc moiety of the ligand conjugated to the sense strand of the siRNA.


Subject(s)
Asialoglycoprotein Receptor , Galactosamine , RNA, Small Interfering , RNA-Induced Silencing Complex , Animals , Mice , Acetylgalactosamine/chemistry , Asialoglycoprotein Receptor/metabolism , Glycoside Hydrolases/metabolism , Glycosides/metabolism , Hepatocytes/metabolism , Ligands , RNA, Small Interfering/metabolism , RNA-Induced Silencing Complex/metabolism
2.
Nucleic Acids Res ; 47(7): 3306-3320, 2019 04 23.
Article in English | MEDLINE | ID: mdl-30820542

ABSTRACT

For oligonucleotide therapeutics, chemical modifications of the sugar-phosphate backbone are frequently used to confer drug-like properties. Because 2'-deoxy-2'-fluoro (2'-F) nucleotides are not known to occur naturally, their safety profile was assessed when used in revusiran and ALN-TTRSC02, two short interfering RNAs (siRNAs), of the same sequence but different chemical modification pattern and metabolic stability, conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Exposure to 2'-F-monomer metabolites was low and transient in rats and humans. In vitro, 2'-F-nucleoside 5'-triphosphates were neither inhibitors nor preferred substrates for human polymerases, and no obligate or non-obligate chain termination was observed. Modest effects on cell viability and mitochondrial DNA were observed in vitro in a subset of cell types at high concentrations of 2'-F-nucleosides, typically not attained in vivo. No apparent functional impact on mitochondria and no significant accumulation of 2'-F-monomers were observed after weekly administration of two GalNAc-siRNA conjugates in rats for ∼2 years. Taken together, the results support the conclusion that 2'-F nucleotides can be safely applied for the design of metabolically stabilized therapeutic GalNAc-siRNAs with favorable potency and prolonged duration of activity allowing for low dose and infrequent dosing.


Subject(s)
Acetylgalactosamine/adverse effects , Acetylgalactosamine/chemistry , Deoxyribonucleotides/adverse effects , Deoxyribonucleotides/chemistry , Fluorine/chemistry , RNA, Small Interfering/adverse effects , RNA, Small Interfering/chemistry , Animals , Female , Fluorine/adverse effects , Humans , Male , Rats , Rats, Sprague-Dawley
3.
Mol Syst Biol ; 14(10): e8009, 2018 10 04.
Article in English | MEDLINE | ID: mdl-30287681

ABSTRACT

Among components of the translational machinery, ribonucleoside modifications on tRNAs are emerging as critical regulators of cell physiology and stress response. Here, we demonstrate highly coordinated behavior of the repertoire of tRNA modifications of Plasmodium falciparum throughout the intra-erythrocytic developmental cycle (IDC). We observed both a synchronized increase in 22 of 28 modifications from ring to trophozoite stage, consistent with tRNA maturation during translational up-regulation, and asynchronous changes in six modifications. Quantitative analysis of ~2,100 proteins across the IDC revealed that up- and down-regulated proteins in late but not early stages have a marked codon bias that directly correlates with parallel changes in tRNA modifications and enhanced translational efficiency. We thus propose a model in which tRNA modifications modulate the abundance of stage-specific proteins by enhancing translation efficiency of codon-biased transcripts for critical genes. These findings reveal novel epitranscriptomic and translational control mechanisms in the development and pathogenesis of Plasmodium parasites.


Subject(s)
Plasmodium falciparum/physiology , Protozoan Proteins/genetics , Protozoan Proteins/metabolism , RNA, Transfer/metabolism , Codon , Epigenesis, Genetic , Erythrocytes , Gene Expression Profiling/methods , Gene Expression Regulation , Humans , Plasmodium falciparum/genetics , Protein Biosynthesis , Protein Processing, Post-Translational , Proteomics/methods
4.
Nucleic Acids Res ; 45(19): 10969-10977, 2017 Nov 02.
Article in English | MEDLINE | ID: mdl-28981809

ABSTRACT

Covalent attachment of a synthetic triantennary N-acetylagalactosamine (GalNAc) ligand to chemically modified siRNA has enabled asialoglycoprotein (ASGPR)-mediated targeted delivery of therapeutically active siRNAs to hepatocytes in vivo. This approach has become transformative for the delivery of RNAi therapeutics as well as other classes of investigational oligonucleotide therapeutics to the liver. For efficient functional delivery of intact drug into the desired subcellular compartment, however, it is critical that the nucleic acids are stabilized against nucleolytic degradation. Here, we compared two siRNAs of the same sequence but with different modification pattern resulting in different degrees of protection against nuclease activity. In vitro stability studies in different biological matrices show that 5'-exonuclease is the most prevalent nuclease activity in endo-lysosomal compartments and that additional stabilization in the 5'-regions of both siRNA strands significantly enhances the overall metabolic stability of GalNAc-siRNA conjugates. In good agreement with in vitro findings, the enhanced stability translated into substantially improved liver exposure, gene silencing efficacy and duration of effect in mice. Follow-up studies with a second set of conjugates targeting a different transcript confirmed the previous results, provided additional insights into kinetics of RISC loading and demonstrated excellent translation to non-human primates.


Subject(s)
Acetylgalactosamine/pharmacokinetics , Kidney/metabolism , Liver/metabolism , RNA, Small Interfering/pharmacokinetics , Acetylgalactosamine/administration & dosage , Acetylgalactosamine/metabolism , Animals , Area Under Curve , Drug Delivery Systems/methods , Humans , Liver/cytology , Male , Metabolic Clearance Rate , Mice, Inbred C57BL , RNA Interference , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...